Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, lenalidomide (Revlimid®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. |
||
|
||
Medicine details |
||
| Medicine name | lenalidomide (Revlimid®) | |
| Formulation | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsule | |
| Reference number | 1585 | |
| Indication | Treatment of adult patients with relapsed or refractory mantle cell lymphoma |
|
| Company | Celgene Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 20/10/2016 | |